- N9030AK-RT1 real-time spectrum analyzer up to 85-MHz bandwidth: $7,224.
- N9030AK-RT2 real-time spectrum analyzer up to 160-MHz bandwidth: $10,320.
What's next for shares of Agilent Technology.
Agilent turned in another stellar earnings results.
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
U.S. stock futures are higher on Tuesday.